Related Experiment Video
Updated: Jul 11, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.1K
Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression
Ahmed Elmosalamy1, Nicola Keeth2, Jin Hong Park3
1Elmosalamy, MBBCh, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Psychopharmacology Bulletin
|July 9, 2025
Summary
Second-generation antidepressant monotherapy shows promise for bipolar II depression, offering similar response rates to lithium without increased switch risk. Further research is needed to confirm long-term effectiveness and guide personalized treatment.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Bipolar II disorder (BD-II) is characterized by frequent depressive episodes and limited FDA-approved treatments.
- Despite this, monoaminergic antidepressants are frequently prescribed off-label for BD-II depression.
- This highlights a critical need for evidence-based treatment options.
Purpose of the Study:
- To systematically review the evidence for second-generation antidepressant (SGAD) monotherapy in treating acute bipolar II depression.
- To update the current understanding of SGAD efficacy and safety in this patient population.
Main Methods:
- A comprehensive literature search was conducted across multiple databases (MEDLINE, Embase, CENTRAL, PsycINFO, Scopus, Web of Science) from March 2021 to February 2025.
- Included studies were randomized controlled trials (RCTs) assessing SGAD monotherapy in adults with acute BD-II depression.
- Primary outcomes evaluated included response, remission, treatment-emergent affective switch (TEAS), and adverse event (AE) related discontinuations.
Main Results:
- Six RCTs (four double-blind, one open-label, one triple-blind) involving 666 patients were included.
- Venlafaxine and sertraline demonstrated short-term efficacy, with response rates between 60.4%-73.3% and remission rates between 44.2%-58.5%.
- The risk of TEAS was below 19.9% and comparable to lithium; AE withdrawals were similar, and SGADs showed comparable or better all-cause discontinuation rates.
Conclusions:
- Limited short-term data suggest SGAD monotherapy is well-tolerated for acute BD-II depression, with response rates similar to lithium and no increased risk of affective switch.
- The current evidence base is small and heterogeneous, necessitating larger, longer-term RCTs.
- Future research should focus on confirming efficacy, assessing maintenance benefits, and informing personalized treatment strategies for BD-II depression.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:30Bipolar Disorder
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.